PARI Pharma Presents Study Results of Sinus Delivery and InhaledLiposomal Ciclosporin A at European Cystic Fibrosis Conference
MUNICH, Germany, June 14, 2007 /PRNewswire/ -- PARI Pharma will present in-vivo study results for their PARI SINUS pulsating drug delivery system as well as lung deposition and pharmacokinetic data of their proprietary inhaled liposomal Ciclosporin A formulation in lung transplant patients at the European Cystic Fibrosis Conference (ECFC) in Belek, Turkey this week.
Continuing their tradition of developing highly advanced inhalation delivery platforms, PARI has created a pulsating sinus drug delivery system to target the upper respiratory tract. Study results at ECFC will focus on visual deposition results using dynamic 81mKr-gas ventilation imaging.
In a separate poster presentation, study results will be presented showing lung deposition and pharmacokinetics of inhaled Ciclosporin A given to 12 lung transplanted patients using PARI Pharma's proprietary liposomal platform technology delivered via a customized eFlow electronic nebulizer. Inhaled Ciclosporin A is a potential therapy for lung transplant patients that is hoped to improve survival rates while reducing side effects by targeting drug delivery of a Ciclosporin A formulation with eFlow so that lower doses of drug may be effective. Using a vibrating membrane, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time.
The European Cystic Fibrosis Conference, held by the European Cystic Fibrosis Society, focuses on international advancements in the treatment of cystic fibrosis. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive systems of an estimated 70,000 children and adults worldwide.
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.
Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at http://www.paripharma.com
CONTACT: Kirsten Ayars of Ayars & Associates, +1-805-452-7909, for PARIPharma; or Geoff Hunziker, of PARI Pharma , +1-831-372-3580
Web site: http://www.paripharma.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2007